Cargando…

Does Myasthenia Gravis Affect Long-Term Survival in Thymic Carcinomas? An ESTS Database Analysis

Background: Thymic carcinoma is a rare and highly malignant tumor with a dismal prognosis, which occasionally coexists with myasthenia gravis (MG). This study aims to investigate the MG incidence on a surgical cohort of patients with thymic carcinoma and to explore its influence on long-term surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Lococo, Filippo, Nachira, Dania, Chiappetta, Marco, Evangelista, Jessica, Falcoz, Pierre Emmanuel, Ruffini, Enrico, Van Schil, Paul, Scarci, Marco, Furàk, Jòzsef, Sollitto, Francesco, Guerrera, Francesco, Spaggiari, Lorenzo, Aigner, Clemens, Evangelia, Liverakou, Billè, Andrea, Moser, Bernhard, Thomas, Pascal Alexandre, Liberman, Moishe, Boubia, Souheil, Campisi, Alessio, Ampollini, Luca, Toker, Alper, Enyed, Attila, Voltolini, Luca, Van Raemdonck, Dirk, Margaritora, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319380/
https://www.ncbi.nlm.nih.gov/pubmed/35885668
http://dx.doi.org/10.3390/diagnostics12071764
Descripción
Sumario:Background: Thymic carcinoma is a rare and highly malignant tumor with a dismal prognosis, which occasionally coexists with myasthenia gravis (MG). This study aims to investigate the MG incidence on a surgical cohort of patients with thymic carcinoma and to explore its influence on long-term survival. Methods: the prospectively collected data from the ESTS database on thymic epithelial tumors were reviewed. Clinical, pathological, and survival information on thymic carcinoma were analyzed. Results: the analysis was conducted on 203 patients, with an equal gender distribution (96 males and 107 females). MG was detected in 22 (10.8%) patients, more frequently elderly (>60 years, p = 0.048) and male (p = 0.003). Induction therapy was performed in 22 (10.8%) cases. After surgery, 120 (59.1%) patients had a Masaoka stage II–III while complete resection (R0) was achieved in 158 (77.8%). Adjuvant therapy was performed in 68 cases. Mean follow-up was 60 (SD = 14) months. The 3-year, 5-year and 10-year survival rates were 79%, 75% and 63%, respectively. MG did not seem to influence long-term survival (5-year survival in non-MG–TCs 78% vs. 50% in MG–TCs, p = ns) as age < 60 years, female gender, early Masaoka stage, and postoperative radiotherapy did, conversely. Conclusions: myasthenia occurred in about 10% of thymic carcinomas and it did not seem to affect significantly the long-term prognosis in surgically treated thymic carcinoma-patients.